CytoSorbents Corp (CTSO)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$0.8285
Buy
$0.86
$0.0178 (+2.17%)
Prices updated at 28 May 2025, 17:51 EDT
| Prices minimum 15 mins delay
Prices in USD
CytoSorbents Corp is a immunotherapy company. The Company uses blood purification to modulate inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 70.59 |
| 2023 | 70.62 |
| 2022 | 52.47 |
| 2021 | 72.46 |
| 2020 | 71.99 |
| 2019 | 67.65 |
| 2018 | 63.02 |
| 2017 | 58.76 |
| 2016 | 51.82 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 1.30 |
| 2024 | 1.47 |
| 2023 | 1.57 |
| 2022 | 2.15 |
| 2021 | 4.33 |
| 2020 | 8.34 |
| 2019 | 5.71 |
| 2018 | 12.70 |
| 2017 | 14.89 |
| 2016 | 19.48 |
| 2015 | 39.25 |
Price/Forward earnings (YTD)
-4.32
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -41.30 |
| 2023 | -50.34 |
| 2022 | -42.96 |
| 2021 | -27.37 |
| 2020 | -13.36 |
| 2019 | -62.57 |
| 2018 | -59.04 |
| 2017 | -52.05 |
| 2016 | -112.31 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 4.27 |
| 2023 | 2.26 |
| 2022 | 1.79 |
| 2021 | 1.43 |
| 2020 | 1.14 |
| 2019 | 8.01 |
| 2018 | 2.02 |
| 2017 | 2.35 |
| 2016 | 7.25 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
